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Abstract: Organ-on-a-chip technology has been used in testing small-molecule drugs for screening
potential therapeutics and regulatory protocols. The technology is expected to boost the development
of novel therapies and accelerate the discovery of drug combinations in the coming years. This has
led to the development of multi-organ-on-a-chip (MOC) for recapitulating various organs involved
in the drug–body interactions. In this review, we discuss the current MOCs used in screening
small-molecule drugs and then focus on the dynamic process of drug absorption, distribution,
metabolism, and excretion. We also address appropriate materials used for MOCs at low cost and
scale-up capacity suitable for high-performance analysis of drugs and commercial high-throughput
screening platforms.
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The failure of drug design in clinical trials is rooted in the differences between the
human body and the preclinical animal models, resulting in incorrect predictions of pharmacokinetics and pharmacodynamics, such as clearance, safety margins, toxicity, and efficacy [1,2]. Clinical trials on more than 2000 drugs indicated the incompatibility of animal
test results for toxic responses in the human body [3]. The growing need to develop viable
in vitro alternatives to animal testing has generated the organ-on-chips technology, which
combines biotechnology, cell biology, biomaterials, and biomedical sciences to recapitulate
an organ or tissue microenvironment [4–6]. In contrast to single organ chips, which aim to
recapitulate the biological function of individual organs, multi-organs-on-chips (MOCs) are
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Microfluidic-based devices have been developed based on drug carrier-free and drug
carrier-integrated chips, which also involve a carrier loaded with the therapeutic agent,
enabling spatiotemporal control over the mobility of small-molecule drugs. Compared to
conventional systems, microfluidic devices provide targeted and sustained release, thus
avoiding the burst distribution of drugs that improves safety and compliance through
pain reduction [15]. Modern micro and nanotechnological approaches enable spatial and
temporal control over the release of drugs. We can generate tunable drugs with sustained
drug release properties [16] from fibrous materials [17], microgels [18], hydrogels [19],
polymeric implants [16], and DNA logic gate circuits [20]. The concept of applying microdevices for regulating the release of small molecules emerged in 1998 when Santini et al.
proposed a microchip demonstrating controlled and pulsatile release of single or multiple molecules [21]. The advancements in scientific knowledge and the cross-disciplinary
efforts for recapitulating experiments in more controlled conditions led to MOC developments [22,23].
The recent advances in organ-on-chips and MOCs technologies have been extensively
reviewed in the literature, providing a thorough insight into the development of microphysiological systems resembling the liver and heart [24], intestine [25], lung [26], kidney [27],
and multi-organ [2,28–31] functions for drug discovery and drug toxicity screening applications. Driven by the momentum of MOCs technologies, the current review will cover
the latest advancements and challenges encountered in the field of MOC systems and the
essential parameters for their successful and timely commercialization.
2. Small Molecules: Properties and Applications
Small-molecule drugs have low molecular weights (100–1000 g/mol or 0.1–1 kDa)
and include chemotherapeutics, steroids, and antibiotics. These small-sized molecules
can penetrate the cell membrane and modulate intracellular signaling pathways [32–35].
They can interfere with tumor-induced cell proliferation and development via interrupting
various protein pathways [36]. Off-target effects and limited efficacy of drugs make small
molecules preferred for their site selectivity and sustained release [16]. Different anticancer
drugs have benefited from being small molecules and are applied as protein inhibitors.
MOCs have been used to study the systemic absorption and metabolism of drugs.
They are integrated with micro-pumps and channels to create multi-organ models, such
as the intestine, liver, skin, and kidney [37]. Wagner et al. designed a dynamic MOC by
human liver and skin coculture to investigate the toxicity of troglitazone on day 6 postincubation. Results indicated a dose-dependent response to troglitazone after the 6-day
treatment [38]. In another study, Edington et al. designed an interconnected microfluidic
device made of multi-cultures for modeling the gut, endometrium, lung, liver, heart, and
brain for lipophilic drugs [39].
MOC designs for the blood brain barrier have come into prominence as potential
models to obtain significant predictions for the transport and efficacy of nanomedicine [40].
Miller and Shuler developed a MOC model for a 13-organ system with various cell lines by
mimicking the main parenchymal organs and physiological barrier tissues in the human
body to investigate the inter-organ transport of biological agents for drug response [41].
Mucus is another significant biological barrier for the uptake and absorption of particulate drug carriers. Jia et al. developed a mucus-chip model to optimize the mucosal
absorption of drugs by investigating the penetration and quantifying the transport of
polyethylene glycols-based nanocarriers across the mucus. This mucus-on-chip enabled
effective visualization and quantitative data on the absorption of drug nanocarriers during
muco-penetration [15]. Drug evaluation depends on real-time monitoring of anticancer
drugs in the tumor microenvironment. Tang et al. developed a biomimetic microfluidic
tumor microenvironment consisting of a coculture of tumor and endothelial cells [42]. This
model included a vascular part forming a total lumen under shear flow and communicating
with the 3-D solid tumor part.
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Besides classical microfabrication techniques, 3-D bioprinting has a high potential in
MOC technology using an integrated system in dynamic conditions. In the 3-D bioprinting
technique, with bioinks and a single programmable manufacturing step, the desired
porosity, interconnectivity, and pore design can be easily adjusted, which is critical for
tissue remodeling of the different parts of the body [43]. This technique also has the
advantage of incorporating different types of biomaterials, cells, and biomolecules in a
complex structure within one controllable process step [44], which makes it easy to mimic
a complex organ structure.
3. Organs-on-Chips
3.1. Fabrication Methods
Conventional microfluidics fabrication methods involve the use of lithography-based
molding and casting processes. The processes, such as replica molding, injection molding,
and embossing, assist in fabricating MOCs. Silicon, glass, and plastic materials are used in
such fabrication methods [45]. One key feature is optical transparency, which restricts the
available materials and manufacturing techniques [44]. The use of polydimethylsiloxane
(PDMS) leads to optical transparency, biocompatibility, flexibility, and gas permeability [46].
Among the aforementioned microfluidic fabrications processes, replica molding has
been used to create PDMS microdevices containing microfabricated structures that mimic
the endothelial–epithelial interface [47]. The geometry of this engineered tissue interface
was enhanced to resemble the liver’s blood flow rate and provide proper orientation to rat
hepatocytes (liver epithelial cells) similar to their in vivo alignment along the endotheliumlined sinusoidal barrier. Simple reconstitution of the microarchitecture of this tissue–tissue
interface was sufficient to prompt cultured hepatocytes to self-organize into hepatic cordlike structures and form functional bile canaliculi in vitro even in the absence of living
endothelium. Laser ablation and sacrificial replica molding techniques were applied to
develop microscale 3-D collagen scaffolds replicating human intestinal villi’s geometry [48].
In this work, the culture of human Caco-2 intestinal epithelial cells produced 3-D epithelial
structures exhibited by villi in the human jejunum. A microfabricated breast model was
created by applying a similar kind of PDMS-based replica molding [49]. Engineered
automation can resolve the precision-related and repeatability limitations of in vitro models.
Automated digital microfluidics proved electro-wetting-based control of hepatic organoids
in a microdevice containing a set of electrodes to enumerate the behavior of 3-D hepatic
platforms in media droplets and monitor the hepatic functions [50]. The highly controlled
rate of material exchange and monitoring helped achieve a fast and rapid screening of
the cell–drug interactions. Table 1 summarizes some key properties of materials used
for the fabrication of microfluidic devices. Silicon and glass have been the ancestors of
polymer and hydrogel materials widely adopted in microfluid applications. Among the
polymeric materials commonly used, Teflon is a soft, inert, and optically transparent
material and relatively permeable to gases [51]. Polycarbonate is a durable, transparent,
low-cost material that absorbs UV and has showed low resistance against certain organic
solvents [52,53]. Styrene ethylene butylene styrene is a thermoplastic elastomer optically
transparent, flexible, and adhesive with low partitioning of drugs and small hydrophobic
compounds [54]. Hydrogel-based materials, such as collagen [55,56] and silkworm [57–59],
are biocompatible and bioactive, enhancing cell attachment and proliferation. However,
their poor mechanical properties and low batch-to-batch consistency may compromise
experimental reproducibility and cellular response [60].
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Table 1. Biomaterials used in the fabrication of microfluidic devices.
Material

Relevant Property

Application

References

Teflon

Ease of fabrication with maximum
chemical resistance

Very sensitive assays, ultra-clean tools,
valves, and pumps fabrication

[51]

Acrylonitrile butadiene styrene

High resolution, best topography

Crafting of the master mold, study of
pathogenic organisms

[52]

Styrene ethylene butylene styrene

Low drug absorption,
optical transmittance

Human lung epithelial cells, human
umbilical vein endothelial HUVECs,
human alveolar epithelial cells

[54]

Chitosan

Biocompatible, effective control
of stereochemistry

Biosensors, film organization

[55,56]

Silkworm

Biocompatible, pliable

Fabrication of microfluidic platforms

[57,58]

PDMS

Good turnaround time, multimaterial printing, long-lasting and
high-temperature-resistant substance

Master molding

[59]

Agarose

Minimal toxicity, biodegradability,
tunable stability at a lower solid ratio

Chondrocytes, AML-12 murine
hepatocytes, sensors, and actuators

[61,62]

Photocurable resin/polymer

Effective resolution with
small characters

Study of cell growth

[63,64]

Polyurethane-methacrylate

Economical to manufacture,
biocompatibility, no cytotoxicity,
strong electroosmotic mobility

Increased-aspect-ratio microstructures

[65–67]

Polyhydroxyalkanoates

Biocompatibility, tunable,
biodegradability

Microfilm barrier for vapor and oxygen

[68]

Polyethylene glycols

Cheaper than many of the material,
different weight categories are
available, biocompatible,
cytotoxicity approximately naught

Microfluidic valves, microfluidic
channels with an increased expiry time

[69]

Gelatin methacrylate

Photopolymerizable,
porous membrane

Mechanistic vascular and valvular
biology cell support matrix

[70]

Polylactic acid and
polyglycolic acid

Mechanical biodegradation

Porous scaffold for cell culture with
better adhesion

[71]

Synthetic hydrogels

Induration and contraction act as
sensors and actuators

Self-regulating valves, micro-lens
arrays, drug release, antigen adsorption
flow sensors pH regulators

[72,73]

3.2. Drug Assays
Patients treated with protein-based drugs frequently develop drug-specific neutralizing antibodies, rendering the drugs unavailable to the target sites [74,75]. Neutralizing
antibodies can also adversely affect other organs, as demonstrated by recombinant human
erythropoietin leading to anemia resulting from antibody-dependent immune responses,
which destroy both extrinsic and intrinsic erythropoietin, thus causing abnormal RBC
development and production [76,77].
A study found that the effects on the potency, efficiency, hepatotoxicity, and hematological toxicity of an anticancer medicine (Tegafur) channelized with a microfluidic device
that were not observed in conventional tissue culture more closely mimicked the results
obtained in vivo [78]. Another study observed the previously unknown cardiotoxicity of
a chemotherapeutic drug (bleomycin) because of the crosstalk between the lung and the
heart tissues [79].
In vitro models provide better physiology, immune status, anatomy, drug metabolism,
and host–pathogen interactions [80]. Many drugs have been withdrawn from the market
after obtaining approval for humans because of their toxicity, like hepatotoxicity, liver toxi-
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city, and cardiac toxicity (Table S1). Pergolide drug products, indicated in the treatment of
Parkinson’s disease, have been linked to serious damage in the heart valves of patients [81],
while rofecoxib (Vioxx), a nonsteroidal anti-inflammatory drug, resulted in a higher risk
of heart attack in patients undergoing long-term treatment [81]. Both drugs have been
voluntarily withdrawn from the market owing to their association with cardiac toxicity.
Nefazodone, an antidepressant, and troglitazone (Rezulin), an antidiabetic medication,
have been associated with acute liver injury and death and were withdrawn from the
market due to increased risk of liver toxicity related to their use. The economic burden, the
waste of human-derived resources, and more importantly, the toxic nature of these drugs
to humans had detrimental implications on both patients and pharmaceutical companies.
Therefore, the strategy has been adapted to use testing methods of drug efficacy with
minimal failures.
Another set of microfluidic platforms has been used for studying host–pathogen
interactions to predict drug pharmacokinetic responses in patients [1]. Hepatitis B virus
(HBV) is among the significant health problems that have affected millions around the globe.
A study showed the significance of using the liver-on-a-chip to image HBV interaction
with hepatocytes accurately. Primary rat hepatocytes and immortalized bovine-derived
aortic endothelial cells were cocultured on the opposite sides of a microporous membrane
in a dual microchannel under the continuous flow of culture media. The hepatocytes
maintained their polygonal morphology, physiology, division, and related markers like
albumin and tumor necrosis factor for more than 20 days. The primary rat hepatocytes
were successfully infected with HBV-infected adenovirus. The same model was modified
using the primary human hepatocytes, maintaining their morphology and physiology
for up to 26 days. The secretion of HBV core antigen and HBV DNA was detected after
infection with HBV without adenovirus [82].
The ongoing COVID-19 pandemic has affected billions of lives in one way or another,
calling for an adequate drug or vaccine. A human lung airway chip was developed to
confront the Food and Drug Administration (FDA)-approved medications against SARSCoV-2. This platform was created to mimic the human infection by airborne SARS-CoV-2.
SARS-CoV-2 pseudo particles (CoV-2pp) carrying the SARS-CoV-2 spike proteins (a vital
entry ligand) were channelized into the air channel. They were then exposed to human
lung epithelial cells expressing high levels of TMPRSS2 and ACE2. The study showed
the impact of amodiaquine and toremifene as potential inhibitors of SARS-COV2 in lung
epithelial cells [83,84].
4. High-Throughput Applications and Current Challenges
The use of physiologically relevant MOC models as a screening tool for drug processes in health and disease conditions can accelerate their clinical application and the
bench-to-bedside transition. Although the fast development of high-throughput screening
(HST) has shown successful R&D productivity in the pharmaceutical industry and drug
screening [85,86], there have still been some challenges in the process. First, a complete
system of current HST technologies, including liquid handling equipment, data acquisition,
extensive robotic liquid, and plate handling equipment, is expensive. The high cost of the
HST platforms restricts the screening potential of small molecular targets [87]. Second, the
cost of biological reagents and drug libraries is also high, and the current approaches make
it challenging to reduce reagent consumption. While the volume capacity in a 384-well
plate has been reduced to 100 µL, further minimization of micro-well plates is restricted
due to uncontrolled liquid evaporation. The decrease of the volumes is also limited by
the difficulty of dispensing tiny volumes smaller than ~1 µL [88]. Third, the failure rate
in drug development is high in the clinical phase, and clinical drug development takes
approximately ~63% of the total cost [85,86]. The use of appropriate cell-based assays in
an early, preclinical stage is expected to provide a more efficient way to eliminate possible
false leads due to low drug efficacy or high toxicity [89]. This strategy is complicated for
current HST platforms because cell-based assays are more expensive and require complex
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liquid handling. There is a need for technology with low sample and reagent consumption,
low cost, and cell friendly environment.
4.1. Fabrication Challenges
The majority of microfluidic platforms are dominated by the application of PDMS [90].
However, PDMS-based platforms cannot mimic complex tissue and organ architecture.
The fabrication of multiple PDMS layers requires sequential integration, which is timeconsuming, labor-intensive, and expensive [91]. Apart from PDMS, MOCs may also be
bioprinted. This fabrication technique affects the quality and speed of fabrication of microtissue models [92]. Fabrication based on the use of a laser is limited by pre-application of
cells, inkjet printing has low printing speed and high shear force [93], and extrusion has
low printing speed and resolution.
In contrast, stereolithography has long-term cell viability concerns due to toxicity
issues stemming from the use of radiation due to the application of UV sources [93]. Apart
from the manufacturing techniques of MOCs, the functionalization of these platforms to
mimic organs’ essential functions is crucial [40]. Mimicking these functions allows us to
achieve accurate and reliable preclinical analysis.
The vascular system allows nutrient and oxygen supply and removes metabolic waste
products from the tissues while providing a selective drug barrier [94]. Recapitulating
the in vivo dynamic conditions within the vascular microenvironment can be challenging,
given that blood flow induces constant shear stress on vascular endothelial cells (Figure 2).
In contrast, muscle cell stretching occurs during the cardiac cycle owing to blood vessel
distension. The 3-D microenvironment and the dynamic mechanical events of the cardiac
cycle are critical in maintaining proper vascular cell function. These factors should be
taken into consideration when designing in vitro vascular platforms. The main challenges
encountered during the fabrication of such platforms are related to the assembly, handling,
and using conventional analytical methods [95]. It may also be challenging to adequately
resemble the cylindrical geometry of vascular channels using lithographic techniques since
these typically generate rectangular channels on flat surfaces [96]. Material selection may be
an additional issue to consider regarding biocompatibility and compatibility with specific
assays (Figure 3).
Engineering functional cardiac models that adequately recapitulate the biology of
the heart is highly challenging compared to other tissues. An ideal in vitro model should
mimic the heart’s cellular organization, mechanical contractions, electrical activity, and
transport of molecules. Cardiomyocyte alignment within native heart tissue requires a
proper design on the cell substrate [97]. The intrinsic contractions of the heart tissue are
an additional challenge to be addressed since the simultaneous cardiomyocyte beating
observed in vivo may be easily lost in an in vitro setup [98]. Equally crucial to the recreation
of the microenvironmental cues in a cardiac construct would also be incorporating readout
systems to record cardiac biological functions, such as contractility [99].
4.2. High-Throughput Challenges
To date, different components for cell-based microfluidic high-throughput screening (µHTS) platforms have been developed, including cell culture [88,100], introduction
and transport of samples [101,102], and characterization of cell viability [103,104]. The
microfluidic community has focused on the demonstration of integrating these different
components into a single microfluidic device. Among current microfluidic platforms for
cell-based HST, three major complementary modes of flow manipulation are perfusion
flow, droplet-based, and microarray. Additionally, minimization of the well plate platform reduces reagent consumption, which is difficult due to reagent evaporation and
difficulty in handling [88]. It includes expensive robotic and plate handling equipment
and data acquisition systems [87], in which limitations require a microfluidic platform.
The microfluidic platform provides lower reagent consumption and the ability to control
cellular microenvironments [87]. The µHTS platform involves integrating numerous mi-
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crofluidic components, such as valves, mixers, pumps, and sensors, to control fluid flow
at the microscale [105]. The microfluidic platforms have been continuously used to detect
reagents, particles, cells, or multicellular organisms for chemical and biological analysis.
8 of 22
The detection in droplet and perfusion-based microfluidic channels is usually performed
using optical, electrochemical, Raman, and mass spectrometry.
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In a high-throughput screening platform, making drug gradient increases the capability of parallel screening with different drug concentrations for cell-based drug screening.
The cellular response may be evaluated under multiple doses within the same platform,
saving time and resources. Usually, drug gradient generators are either flow-based or
diffusion-based [106]. However, flow-based gradient generators are popular among pharmaceutical evaluation. “Christmas tree structure”, a flow-based gradient generator, is well
accepted for miniaturized microfluidic devices. The gradient is achieved in a miniaturized
microfluidic network by sequentially diluting concentrations through a mixer [106]. The
selection of the geometry for gradient generation must be considered carefully to produce
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an appropriate shear environment. These selections may be made by proper numerical
9 ofrate
22
simulation studies [107]. The simulation is helpful to determine the gradient and shear
for individual sections with different geometry.
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transport of samples [101,102], and characterization of cell viability [103,104]. The micro‐
fluidic community has focused on the demonstration of integrating these different com‐
ponents into a single microfluidic device. Among current microfluidic platforms for cell‐
based HST, three major complementary modes of flow manipulation are perfusion flow,
droplet‐based, and microarray. Additionally, minimization of the well plate platform re‐
duces reagent consumption, which is difficult due to reagent evaporation and difficulty
in handling [88]. It includes expensive robotic and plate handling equipment and data
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Two-dimensional culture has been widely used for high-throughput screening, but it
fails to replicate the 3-D model of the liver; thus, the 3-D culture technique was developed.
A liver-on-chip platform was designed to recapitulate the native hepatic microenvironment,
provide physiological fluid flow and recapitulate hepatic function (Figure 4A) [113]. The
organ-on-chip has been applied to mimic rat, dog, and human liver platforms, where
the cells were subjected to physiological flow. This platform allows the prediction of
liver toxicity detected in animal studies (Figure 4B) [114]. The platform enables real-time
monitoring using an integrated 3-D bioprinted sensor that can be used in a liver-on-chip
platform. The electrochemical dissolved oxygen sensor was printed inline at multiple
places to monitor oxygen concentration (Figure 4C) [115]. It captured liver function in vitro,
offering a desirable biomimetic microenvironment. The study applied spheroid models,
which enable a high-throughput and parallel culture in a high mass transfer and low shear
for long-term perfusion culture [116]. A large-scale liver-lobule-on-chip platform was
constructed in a hybrid layout with a separate seed-feed network mimicking the 11
central
of 22
vein of the liver lobule. The array allowed passage to transport by diffusion-dominated
mass transport (Figure 4D) [117].
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permission
from
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John
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2021.
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Reprinted with permission from [116], RSC 2018. (C) The liver platform has a cross‐sectional view with an electrochemical
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The MOC high‐throughput screening is performed using a continuous‐flow, droplet‐
high-throughput
screening
performed
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a continuous-flow,
based,The
or MOC
microfluidic
array‐based
platformis[104,118].
The
droplet‐based
platformdropletworks
based,
or
microfluidic
array-based
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[104,118].
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droplet-based
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works
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miniaturized
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that encloseplatform
single orquickly
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that
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drug
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drug
screening.
The
droplet-based
platform
quickly
allows
a
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droplet variants quickly but has limited cell growth in droplets. The continuous‐flow
droplet
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quickly
but
has
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The
continuous-flow
form involves controlling the laminar flow of reagent/media to control the environmental
condition. The control inflow regulates dissolved gas, temperature, pH, and shear stress
inside the microfluidic platform [120]. The application of a continuous‐flow platform is
limited by swelling when exposed to strong solvents, a limited number of the tested ma‐
terial, and the possibility of cross‐contamination. The array‐based microfluidic platform
is more compatible with drug screening since it enables parallel analysis [121] in a high‐
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platform involves controlling the laminar flow of reagent/media to control the environmental condition. The control inflow regulates dissolved gas, temperature, pH, and shear
stress inside the microfluidic platform [120]. The application of a continuous-flow platform
is limited by swelling when exposed to strong solvents, a limited number of the tested
material, and the possibility of cross-contamination. The array-based microfluidic platform is more compatible with drug screening since it enables parallel analysis [121] in a
high-throughput approach. It also provides many samples to analyze the biology and
small-molecule screening [122]. However, a microarray is limited by the inefficient removal
of reagents within the reaction chamber and requires minimal volume detection.
4.2.1. Liver Platforms
The liver is the largest organ in the body consisting of several cell types and the
most complex function [90]. Recapitulation of the liver’s structural, cellular, and localized
hemodynamic complexity is one of the major challenges in developing organotypic in vitro
liver models [123,124]. Even though primary hepatocytes have been the gold standard in
liver chips, their dedifferentiation in vitro has led to the use of alternative cell sources, such
as mutable human embryonic stem cells and iPSCs. The first steps in attaining structural
biomimicry have been made with bile tube simulation, yet functional biomimicry, such
as bile acid secretion, is still in progress. The lack of testing standards, uniformity, realtime monitoring, and the relatively low throughput of liver chips are additional technical
challenges to be resolved with the integration of biosensors within liver devices [125].
Drug metabolism and detoxification processes are additional challenges to be addressed in the liver. As a potential drug carrier, the metabolic fate of nanoparticles and
their effect on human tissues has been intensively investigated. Within this context, Esch
et al. assembled a chip based on the coculture of enterocytes, Caco-2, and mucin-producing
HT29-MTX cells, and HepG2/C3A liver cells to mimic the oral uptake of carboxylated
polystyrene nanoparticles (50 nm) and their effects on the liver. The Caco-2/HT29-MTX
coculture posed an effective barrier to nanoparticle permeability across the cell layer, yet the
nanoparticle fraction crossing this layer mediated the release of aspartate aminotransferase,
an indicator of liver cell injury [126].
Liver models have been made by 2-D planar culture, matrix-less and matrix-dependent
3-D culture, layer-by-layer deposition, 3-D bioprinting, microarray, and hanging drops [125].
These fabrication strategies are viable from short- to long-term biological studies. Among
these strategies, 2-D culture, 3-D-based bioprinting, and microarray strategies may be used
for high-throughput screening. These strategies allow the analysis of biological responses
to drugs. Still, they are limited by applying multiple cells in 2-D culture, resolution, and
control over individual cells in bioprinting, and lack of spatial distribution and cellular
interaction in microarray strategies.
4.2.2. Lung Platforms
Lung chips have introduced a credible alternative to 2-D cell cultures, emulating the
microarchitecture and the primary physiological functions of the human lung better to
understand the physiology and pathology of the human lungs and perform drug screening
and toxicological studies [23]. One of the major challenges of microfluidic lung platforms
in their current form is their short life span, owing to their short-term compatibility. The
design of more biorelevant blood flow networks could potentially minimize the foreign
body response, thus providing lung devices for more long-term applications [127].
Benam et al. engineered a human lung small airway chip to recapitulate the features of
asthma and chronic obstructive pulmonary disease (COPD) in vitro and evaluate the therapeutic response in the small airway chips after drug treatment to overcome the challenge of
extending the drug’s residence. The PDMS microfluidic device was constructed using soft
lithography and consisted of two channels separated from a polyester membrane coated on
both sides with type I collagen. Primary human airway epithelial cells and primary human
lung microvascular endothelial cells were cultured on opposite sides of the membrane.
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Epithelium exposure to interleukin-13 and substituting human airway epithelial cells with
epithelial cells from individuals with COPD generated in vitro models of asthma and
COPD, respectively. This represents a challenge for the small airway chip device, providing
a complementary approach to in vivo models by adequately recapitulating the in vivo
organ-level therapeutic responses [128].
Aiming to simulate the lung tumor microenvironment for chemotherapeutic drug
screening applications, a lung ToC device was constructed using an electrospun PLGA
membrane as a substrate for cell culture [129,130]. Exposure of the coculture of human
lung non-small cell lung cancer cell line A549 and human fetal lung fibroblast HFL1 cells
to the epidermal growth factor receptor EGFR-targeted drug gefitinib showed A549 cell
resistance. In contrast, the triple coculture of A549, HFL1, and HUVEC cells resulted in the
A549 cells showing a strong invasive ability and possibly causing HUVECs’ death [129]. In
a similar approach, a PLGA nanofiber/PDMS composite membrane-sandwiched microdevice enabled better simulation of the tumor lung microenvironment from a biophysical and
biochemical perspective, allowing for fluid perfusion under very low shear stress and cell
culture under both normoxic and hypoxic conditions.
4.3. Tumor Platforms
ToC is essential for developing functional, reproducible, and robust microfluidics suitable for drug screening assays. This was exemplified in a colon cancer micro-tumor model
perfused with the anticancer compounds fluorouracil, vincristine, and sorafenib compared
with conventional monolayer cultures of endothelial or tumor cells. Results indicated
that perfusable vascular networks are critical for drug safety evaluation, highlighting an
additional challenge since this model better mimics the physiological microenvironment
than 2-D cell cultures [131].
Identification of optimal chemotherapeutic drug combinations is sometimes essential
to treat invasive carcinomas, such as bladder cancer. The therapeutic potential of a single or
a variety of chemotherapeutic agents has been assessed in a microfluidic platform combining the coculture of the bladder carcinoma cell line T24 with HUVECs and drug transport
across the endothelial monolayer. Results showed that even though complete inhibition of
T24 cell dispersal was attained in monoculture and the presence of all four tested drugs
at a concentration of 10 mM, the same effect was not observed in the T24 and HUVECs
coculture. The microfluidic platform could help define combination chemotherapeutic
strategies that present a significant challenge in vitro to treat aggressive tumors [132]. The
non-specificity of current chemotherapeutic approaches is an additional challenge to be
addressed. Towards this direction, a ToC device using a coculture of human breast cancer
cells and hepatic cells aimed to identify optimum drug concentrations of doxorubicin,
cisplatin, and paclitaxel that could increase drug efficacy against cancer cells and reduce
toxicity against healthy cells [133].
Many improvements have been made in treating various tumor types by researchers
and clinicians. However, most tumor models have poor approximations to patients’ tumors,
and medications with promising tumor model data may still fail in clinical trials [134].
The complex tumor microenvironment (TME) includes different cell types, ECM-derived
physical stresses, oxygen, nutrient, and biochemical gradients supported by a complex
vascular web. Conventional 2-D models cannot mimic the interactive relationships among
these complicated relationships between TME components, such as tumor cells, stromal
cells, and physical and biochemical factors inside living tumors in the presence of blood
vessels [92,135]. Animal tumor models have provided valuable insights into our basic
understanding of tumor biology; however, these models cannot reflect pathogenic processes
in humans due to genetic alterations [136,137]. We still need better tumor models to fully
understand tumor behavior and the TME, including the inflammatory factors, immune
system response effectors and suppressors, cell heterogeneity, and tumor vasculature,
which is significantly different from healthy vasculature. Some models have been used to
assess chemical cues that influence cell migration and invasion through a porous membrane
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that separates two chambers in Transwell containers [138]. Multicellular tumor spheroids
can mimic cell–cell and cell–ECM interactions between tumor cells and the TME. Spheroids
may develop oxygen and nutrition gradients, resulting in an established necrotic core
similar to poorly vascularized tumor tissue [139,140]. In vitro spheroids still lack the tumor
vasculature in the TME.
Since establishing the first human cancer cell line HeLa, cancer disease models clearly
illustrate an evolving nature from 2-D simple models to complex hydrogel-based organoid
models (Figure 5B). Microfluidics technology has been considered a gamechanger in tumor
modeling because manipulating a few chemical agents has allowed researchers to preserve
tumor cells in a controlled encasement while the flow of the culture medium imposes
the dynamic physiological factors in the vasculature. Researchers use soft lithography
or 3-D printers to create 3-D channels and chambers in PDMS or other flexible polymers.
The micro-channels are connected in micro-chambers, where cells can be captured and
aggregated. Hydrogels containing cells or fluid are perfused into the built-in channels and
chambers to simulate the ECM cues. By continuous perfusion of nutrients and oxygen and
the removal of waste products, microfluidic devices can imitate the in vivo fluid dynamics
of the TME. The interstitial pressure, soluble factor gradients, and oxygen tension are all
physicochemical parameters that microfluidic devices can precisely control [141]. ToC has
been developed for low-cost and high-throughput anticancer drug screening in precision
medicine [142].
To investigate cancer cell migration and invasion and extracellular signaling, as well as
chemotherapy and immunotherapy resistance mechanisms, multiple 3-D tumor-on-a-chip
models have been demonstrated to replicate diverse forms of solid and liquid TMEs, including different stromal components, immune suppressor cells, and chemokines [143–146].
Cui et al. [147] reported a glioblastoma (GBM) on-chip platform mimicking the several
GBM tumor niche subtypes (proneural, classic, and mesenchymal). The chip consists of a
peripheral channel. ECs formed a vascular channel, an intermediate tumor-stromal zone,
where patient-derived GBM cells, tumor-derived macrophages (TAMs), and T-cells can
interact with a central port. They demonstrated an immunosuppressive tumor microenvironment analyzing cytotoxic activity and significantly reducing T-cell activation and
cytotoxic function in GBM tumor niche subtypes. Similarly, Jerkins et al. [147] demonstrated a tumor spheroids model to investigate the PD-1 blockade profile by recapitulating
the native tumor immune microenvironment. They showed that a short-term organotypic
tumor spheroid microfluidic model could recapitulate response to PD-1 blockade and
identify specific interventions that counteract resistance.
Multicellular aggregates and tumor aggregates, namely spheroids, have been used
as tumor models over the years under static conditions [148]. However, these models
have failed to capture the effect of blood flow. Vascularized tumor models are highly
promising to mimic a hostile TME that leads to cancer progression and drug resistance.
Nashimoto et al. [149] demonstrated the importance of flow in a vascular network in TME
to evaluate tumor activities as a drug screening platform. They fabricated a tumor-on-chip
platform that enables monitoring and assessing tumor response with intraluminal flow
combining the PDMS microfluidics with multicellular tumor spheroid-embedded hydrogel.
They showed that drug administration under perfused conditions did not demonstrate
the dose-dependent effects of anticancer drugs on tumor activities compared to the results
under static conditions.
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established mechanism of action or toxicity. Within this context, MOCs could prove
a useful preclinical tool in screening drug toxicity and efficacy and could potentially
substitute animal models and support the findings of phase I and phase II clinical trials.
At the same time, the use of patient-derived cell sources could additionally introduce the
element of personalization. However, it is critical to establish functional and dynamic
collaborations between the academic, industrial, and regulatory sectors to bridge the
existing translational chasm.
The FDA, the US National Institutes of Health (NIH), and the Defense Advanced
Research Projects Agency (DARPA) have acted on this demand by providing funding
opportunities for the development of organs-on-chips and the regulatory support required
to set the roadmap towards market [152]. In Europe, the human Organ and Disease Model
Technologies (DMT) consortium recently joined forces with 21 companies, three knowledge
institutions, and two foundations to develop a flexible ‘SMART Organ-on-Chip’ under the
auspice of an NWO ‘Perspective’ grant. The Asia-Pacific region is witnessing exponential
market growth rates, mainly due to the government funding opportunities provided to
research institutes, especially in China, and the increasing number of clinical trials based
on cell studies [147]. The startup founding dynamics, especially within academic settings,
is also a striking example of the continuous and comprehensive efforts to bring the MOCs
technology to the market. Emulate is a microfluidics startup founded in the Wyss Institute
for Biologically Inspired Engineering in Harvard that has established collaborations with
AstraZeneca and Johnson & Johnson to enable more precise predictions of the effects
of drugs on humans. InSphero, created at the Zurich university in Switzerland, aims
to develop safer and more efficient drugs. AxoSim (Tulane University), TaraBiosystems
(Columbia University, New York, NY, USA), and Nortis Bio (University of Washington,
Washington, DC, USA) focus on the development of nerves-on-chip, heart-on-chip, and
kidneys-on-chip devices, respectively. At the same time, TissUse (Technische University,
Berlin, Germany) has recently introduced a MOC with four organs integrated on the same
chip, further aiming to develop a human-on-chip with 10 organs. It, therefore, is clear that
only through coordinated efforts from all stakeholders will the MOC technology flourish
and find its place among well-established models and procedures for small-molecule
drug testing.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/pharmaceutics13101657/s1, Table S1. Drugs that have been withdrawn from the market
owing to their toxicity.
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